Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer.

ABSTRACT:

Background

Breast cancer concern is a major reason for the recent marked reduction in use of postmenopausal hormone therapy, although equally effective means of controlling menopausal symptoms are lacking. Single nucleotide polymorphisms (SNP) in the fibroblast growth factor receptor 2 (FGFR2) gene are substantially associated with postmenopausal breast cancer risk and could influence hormone therapy effects.

Participants and methods

We interrogated eight SNPs in intron 2 of the FGFR2 gene for 2,166 invasive breast cancer cases from the Women's Health Initiative clinical trial and one-to-one matched controls to confirm an association with breast cancer risk. We used case-only analyses to examine the dependence of estrogen plus progestin and estrogen-alone odds ratios on SNP

SUBMITTER: Prentice RL 

PROVIDER: S-EPMC2783392 | biostudies-literature | 2009 Nov

REPOSITORIES: biostudies-literature